NASDAQ$CAI
Caris Life Sciences Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Caris Life Sciences reported Q1 2026 total revenue of $216.2M (+79% YoY) with a net loss.
Caris posted Q1 2026 total revenue of $216.2 million (+79% YoY) as molecular profiling volume grew, while remaining net loss-making as it invests in commercial expansion and R&D for precision oncology diagnostics.
- Revenue $216.2M (+79%).
- Precision oncology testing scale.
- Net loss continues.
- Payer coverage expanding.
- Competitive NGS profiling market.
Headline financials
Revenue & EPS history
Caris Life Sciences Inc · Revenue · Quarterly
$216M
Forward guidance
Test volume and reimbursement milestones in MD&A.
Tailwinds
- Rapid revenue growth.
- Large addressable market.
- Clinical data moat.
Headwinds
- Path to profitability uncertain.
- Reimbursement risk.
- Cash burn rate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports · overlaid with Q1 2026
-5.8%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-3.7%
Avg return
30 days after
33%
1 / 3 earnings
Positive
+7.4%
Q2 2025
Best reaction
-18.6%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -18.6% | -26.0% | -16.8% | |
| Q3 2025 | -6.3% | -20.5% | -7.4% | |
| Q2 2025 | +7.4% | +20.8% | +13.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro